Nuvalent, Inc. (NUVL)
Market Cap | 4.71B |
Revenue (ttm) | n/a |
Net Income (ttm) | -145.51M |
Shares Out | 64.56M |
EPS (ttm) | -2.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 303,574 |
Open | 75.53 |
Previous Close | 75.51 |
Day's Range | 71.34 - 75.56 |
52-Week Range | 38.78 - 89.39 |
Beta | 1.27 |
Analysts | Strong Buy |
Price Target | 89.78 (+22.99%) |
Earnings Date | Aug 8, 2024 |
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $89.78, which is an increase of 22.99% from the latest price.
News
Nuvalent (NUVL) CEO On The Future Of Cancer Treatments
Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655.
![](https://cdn.snapi.dev/images/v1/z/m/conf5-2451080.jpg)
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/j/w/press9-2435955.jpg)
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/g/d/press13-2420337.jpg)
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 C...
![](https://cdn.snapi.dev/images/v1/y/e/press3-2361948.jpg)
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile Zidesamtinib shown to be ...
![](https://cdn.snapi.dev/images/v1/u/k/conf17-2309742.jpg)
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/e/f/press16-2295304.jpg)
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on crea...
![](https://cdn.snapi.dev/images/v1/j/g/press14-2295275.jpg)
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
![](https://cdn.snapi.dev/images/v1/y/y/press17-2271044.jpg)
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive...
![](https://cdn.snapi.dev/images/v1/l/5/press12-2254892.jpg)
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/w/9/press19-2219758.jpg)
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTarget 2026 initiatives wit...
![](https://cdn.snapi.dev/images/v1/l/g/conf2-2204629.jpg)
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
![](https://cdn.snapi.dev/images/v1/r/q/press1-2156311.jpg)
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development Appo...
![](https://cdn.snapi.dev/images/v1/z/y/press1-2132295.jpg)
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/l/8/press12-2105828.jpg)
Nuvalent Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/f/t/press7-2104294.jpg)
Nuvalent Announces Public Offering of Common Stock
CAMBRIDGE, Mass. , Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
![](https://cdn.snapi.dev/images/v1/t/1/press19-2102180.jpg)
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
Encouraging preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and...
![](https://cdn.snapi.dev/images/v1/o/t/press9-2089979.jpg)
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
Updated preliminary data to be presented at the 35th AACR-NCI-EORTC Symposium Company plans to host a conference call on October 13, 2023 at 8:00am EDT CAMBRIDGE, Mass. , Oct. 4, 2023 /PRNewswire/ -- ...
![](https://cdn.snapi.dev/images/v1/w/x/conf5-2066828.jpg)
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creat...
![](https://cdn.snapi.dev/images/v1/q/z/press15-2048823.jpg)
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stag...
![](https://cdn.snapi.dev/images/v1/p/o/conf7-2044369.jpg)
Nuvalent to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
![](https://cdn.snapi.dev/images/v1/s/t/press17-2016681.jpg)
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
Continued execution across pipeline with clinical trials ongoing for NVL-520 and NVL-655, and advancement of NVL-330 toward clinical development Preliminary dose-escalation data anticipated from ongoi...
![](https://cdn.snapi.dev/images/v1/l/c/conf18-1998305.jpg)
Nuvalent to Participate in Upcoming August Investor Conferences
CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/c/l/press16-1904773.jpg)
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
CAMBRIDGE, Mass. , May 24, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
![](https://cdn.snapi.dev/images/v1/y/s/press20-1884543.jpg)
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors Stron...